5.7 Times more expensive than liquid gold

Bowler, Gordon; Fayers, Tessa; Gouws, Pieter

doi:10.1136/bjophthalmol-2011-301241

Cited by 5 publications

(3 citation statements)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The infrastructure required to detect AMD and deliver treatment as well as the cost of treatment itself is currently prohibitively expensive for use in most LMIC settings but is widely used in high‐income countries (Bowler et al . ). Vitamin supplementation has shown some evidence of risk reduction in progression of subtypes of AMD (Evans ), but not prevention of AMD (Evans & Lawrenson ) and again may be prohibitively expensive.…”

Section: Discussionmentioning

confidence: 97%

Posterior segment eye disease in sub‐Saharan Africa: review of recent population‐based studies

Bastawrous

Burgess

Abdull

et al. 2014

Tropical Med Int Health

View full text Add to dashboard Cite

ObjectiveTo assess the burden of posterior segment eye diseases (PSEDs) in sub-Saharan Africa (SSA).MethodsWe reviewed published population-based data from SSA and other relevant populations on the leading PSED, specifically glaucoma, diabetic retinopathy and age-related macular degeneration, as causes of blindness and visual impairment in adults. Data were extracted from population-based studies conducted in SSA and elsewhere where relevant.ResultsPSEDs, when grouped or as individual diseases, are a major contributor to blindness and visual impairment in SSA. PSED, grouped together, was usually the second leading cause of blindness after cataract, ranging as a proportion of blindness from 13 to 37%.ConclusionsPSEDs are likely to grow in importance as causes of visual impairment and blindness in SSA in the coming years as populations grow, age and become more urban in lifestyle. African-based cohort studies are required to help estimate present and future needs and plan services to prevent avoidable blindness.

show abstract

Section: Discussionmentioning

confidence: 97%

Posterior segment eye disease in sub‐Saharan Africa: review of recent population‐based studies

Bastawrous

Burgess

Abdull

et al. 2014

Tropical Med Int Health

View full text Add to dashboard Cite

show abstract

“…Most of the posterior segment disorders are difficult to treat and established visual loss is difficult to reverse as for many PSEDS there is no 'curative' treatment [2]. Unfortunately, the infrastructure required to detect and treat PSED is very costly and often unavailable in most eye care centers [3]. In addition, highly skilled staff required for conducting posterior segment surgical interventions is not commonly available in most of the medical centers and hospitals.…”

Section: Introductionmentioning

confidence: 99%

Posterior segment eye diseases: prevalence, pattern, and attribution to visual impairment among adult saudi population

Elmorsy¹

2019

Ann Clin Anal Med

View full text Add to dashboard Cite

Aim: In this study, we aimed to investigate the prevalence and pattern of posterior segment eye disease (PSEDs) and their attribution to visual impairment (VI) in Saudi adults of Arar city, Saudi Arabia. Material and Method: Prevalence and pattern of PSEDs were studied through ophthalmological evaluation including B-scan ultrasonography on 956 participants from Arar city. Results: The prevalence of PSEDs in the current study was 10.7%. Diabetic retinopathy (DR) was the commonest pathology found in 64 (6.7%) participants. Age-related macular degeneration (ARMD), optic atrophy (OA) and retinal detachment (RD) were found in 19 (2%), 16 (1.7%) and 10 (1%) cases respectively. Glaucoma was the commonest cause of OA found in 50% of cases. DR and high myopia were found to be the underlying cause in about 50% of RD cases. Vitreous hemorrhages in association with DR, ARMD, and RD were found in 39 (4%) cases. The current study revealed that DR was the commonest PSED diagnosed in cases of VI. Discussion: These data highlight the magnitude of the PSEDs as the causes of visual impairment and encourage proper healthcare planning to reduce the burden of the posterior segment eye diseases.

show abstract

“…The cost difference in the USA is nearly 35–40-fold less for bevacizumab (∼US$50) compared with ranibizumab (∼US$2000), aflibercept (∼US$1800) 9 10. For perspective, gold (as of now) is trading at ∼US$1800 an ounce which, as one recent article has mentioned, places the equivalent volume of liquid gold at approximately 5–6 times less than ranibizumab or aflibercept 11. What we want as a medical community is the best investment for our patients’ future vision and health; and to that end, our search continues for answers related to the relative efficacy, safety and value of these drugs so that we can help guide our patients towards the best therapeutic decision for them.…”

mentioning

confidence: 99%

The MANTA 1-year results: the anti-VEGF debate continues: Table 1

Ehlers

2012

Br J Ophthalmol

View full text Add to dashboard Cite

5.7 Times more expensive than liquid gold

Cited by 5 publications

References 2 publications

Posterior segment eye disease in sub‐Saharan Africa: review of recent population‐based studies

Posterior segment eye disease in sub‐Saharan Africa: review of recent population‐based studies

Posterior segment eye diseases: prevalence, pattern, and attribution to visual impairment among adult saudi population

The MANTA 1-year results: the anti-VEGF debate continues: Table 1

Contact Info

Product

Resources

About